When should teams reconsider the 510(k) strategy?

If intended use alignment is weak, technology differences are major, or the evidence burden becomes disproportionate, teams should reassess regulatory strategy before drafting a full filing package.

FDA 510(k) Predicate Analysis Scorecard & Decision Tool

Q: Can one score alone justify filing?

No. The score is an internal planning signal. Teams should still confirm intended use alignment, evidence quality, and final submission completeness against FDA expectations.

Q: Should we use multiple predicates?

Many teams choose one primary predicate and add secondary predicates for specific features. The key is to clearly explain why each comparator is relevant and how differences are controlled with data.

This utility helps device teams pressure-test whether a candidate predicate can support a clear, defensible substantial equivalence argument. It is a practical planning aid, not legal advice and not a substitute for FDA review.

Use Tool 1 to score your candidate predicate profile across the highest-impact dimensions. Then use the decision matrix and checklist to assign owners, evidence requirements, and filing readiness gates before you lock a primary predicate strategy.

Need End-to-End 510(k) Execution Support?

Cruxi helps teams structure predicate strategy, map evidence to claims, and prepare coherent 510(k) submissions in an eSTAR-ready workflow.

Explore 510(k) Submission Services

How To Use This Utility

Step 1: Score Predicate Fit

check_circle
Rate each domain from 0 to 5 using objective documents, not assumptions.
check_circle
Run the scorecard to view weighted fit score and top risk drivers.
check_circle
Use priority output to focus evidence generation where risk is highest.

Step 2: Set Go/No-Go Gate

check_circle
Complete the decision matrix with evidence sources and owner names.
check_circle
Verify each major technology difference has test support or rationale.
check_circle
Decide file now, strengthen dossier first, or reassess pathway.

Utility Tool 1: Predicate Candidate Fit Scorecard

Score each domain from 0 (weak) to 5 (strong)

Weights reflect common pressure points that can weaken substantial equivalence arguments and increase review-cycle risk.

Intended use fit (weight 22) Similarity of indications for use and clinical context.

Technology similarity (weight 18) Design, energy source, operating principles, critical components.

New risk control clarity (weight 14) Evidence and rationale for differences that may affect risk profile.

Testing traceability to claims (weight 16) Clear link from each key claim to supporting performance data.

Predicate regulatory history quality (weight 10) Recall posture, recentness, and confidence in comparator relevance.

510(k) summary detail quality (weight 8) Availability of useful detail for side-by-side comparison.

Labeling and IFU alignment (weight 6) Consistency across indications, warnings, contraindications, and use steps.

Evidence readiness before filing (weight 6) Maturity of test reports, protocols, and integrated rationale language.

Run the scorecard to view weighted predicate fit, risk band, and highest-impact gaps to close before filing.

Predicate Decision Matrix Template

Use this matrix in your internal review meeting to decide whether your current candidate remains primary, needs a secondary comparator, or should be replaced.

Decision Dimension	Evidence To Verify	Minimum Gate	Owner
Intended use equivalence	Subject IFU + predicate indications language with line-by-line mapping	No clinically meaningful mismatch	Regulatory lead
Technology differences	Comparison table covering architecture, materials, energy, software behavior	Differences explained without new unresolved safety questions	Systems + regulatory
Performance evidence burden	Claims-to-test traceability matrix with acceptance criteria and endpoints	Each critical claim mapped to complete evidence package	Verification lead
Labeling coherence	Draft labeling, contraindications, warnings, and user instructions review	No contradiction between claims, test scope, and labeling	Clinical + RA
Submission readiness	SE narrative draft, summary sections, and eSTAR section completeness	All major rationale statements backed by referenced evidence	Submission owner

Interpretation Bands

Strong Candidate (80-100)

Predicate strategy appears viable. Focus on narrative quality, evidence cross-references, and final consistency checks before filing.

Borderline Candidate (60-79)

Potentially workable with focused risk reduction. Close top scorecard gaps and reassess before finalizing comparator strategy.

Weak Candidate (<60)

Current predicate strategy likely to create avoidable friction. Re-scope comparator plan or strengthen evidence package significantly.

Pre-File Predicate Strategy Checklist

task_alt
Primary predicate selection rationale documented and approved by cross-functional reviewers.
task_alt
All major technology differences linked to clear test or risk-control evidence.
task_alt
Labeling language reviewed against intended use and comparison claims.
task_alt
SE narrative draft reviewed for logic gaps, unsupported claims, and citation completeness.
task_alt
Backup comparator options identified in case primary strategy weakens late in preparation.

Related 510(k) Resources

link
510(k) Submission Services for end-to-end filing support.
link
Substantial Equivalence Guide to structure difference justifications.
link
FDA Database Research Guide for practical predicate search workflows.
link
RTA Deficiency Risk Estimator to pressure-test full submission readiness.

Frequently Asked Questions

Can one score alone justify filing?

No. This scorecard is a planning signal. Teams should still verify overall evidence quality, consistency, and complete submission structure.

Should we use multiple predicates?

Many teams use one primary predicate and secondary comparators for specific features. What matters is coherent logic and data support for each comparator.

When should teams reconsider their 510(k) predicate strategy?

If intended use fit is weak, critical differences remain unresolved, or the evidence burden keeps expanding, reassess strategy before finalizing the filing plan.

References & Citations

This utility is grounded in official FDA resources and intended for internal planning use.